CN109422751B - Compound with activity of degrading tyrosine protein kinase JAK3 - Google Patents
Compound with activity of degrading tyrosine protein kinase JAK3 Download PDFInfo
- Publication number
- CN109422751B CN109422751B CN201710783074.0A CN201710783074A CN109422751B CN 109422751 B CN109422751 B CN 109422751B CN 201710783074 A CN201710783074 A CN 201710783074A CN 109422751 B CN109422751 B CN 109422751B
- Authority
- CN
- China
- Prior art keywords
- substituents
- compound
- integer
- group
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
The invention provides a compound with activity of degrading tyrosine protein kinase JAK3, in particular to a compound shown as the following formula I; wherein, the definition of each group is as the specificationThe method as described in (1). The compound has good JAK3 degradation activity, and can be used for preparing medicines for treating diseases related to JAK 3.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a compound with the activity of degrading tyrosine protein kinase JAK3, and preparation and application thereof.
Background
Janus kinases (JAKs) are non-receptor tyrosine protein kinases existing in cells, are very important for multiple functions such as growth, activation and homeostatic regulation of T cells, and play a key role in regulating the cell functions of the lymphohematopoietic system. In mammals, this family contains 4 major family members, namely JAK1, JAK2, JAK3 and Tyk 2. Among them, JAK1, JAK2 and Tyk2 are widely expressed in various histiocytes, and JAK3 is mainly expressed in hematopoietic tissues at high efficiency, such as activated B lymphocytes, T lymphocytes, bone marrow cells and thymocytes.
Due to the wide regulation of the JAK3-STAT signal pathway, organ transplant rejection, xenotransplantation, lupus erythematosus, multiple sclerosis, rheumatoid arthritis, psoriasis, cancer, asthma, atopic dermatitis, type I diabetes and diabetic complications, autoimmune thyroid disorders, ulcerative colitis, crohn's disease, alzheimer's disease, leukemia, lymphoma, multiple myeloma, alopecia areata, vitiligo and many other diseases occur, JAK3 is also involved, JAK3 plays a key role in disease occurrence as a signal transmission member, and becomes a drug target for developing and treating such diseases in medicine development.
Therefore, the skilled person is working to develop compounds capable of inhibiting JAK3 activity.
Disclosure of Invention
The invention aims to provide a compound capable of inhibiting and degrading JAK3, and preparation and application thereof.
In a first aspect of the invention, there is provided a compound of formula I, or a pharmaceutically acceptable salt thereof:
wherein:
-represents a single bond;
a is absent or selected from C (═ O), C (═ O) X1, SOX1, SO2X1, C with or without substituents1-8Hydrocarbyl, C with or without substituents1-8Cyclic hydrocarbonsA group, and C with or without a substituent1-8A heterocyclic hydrocarbon group; wherein X1 is absent or selected from (CR)12R13)eO、(CR12R13)eS and NR14(ii) a Wherein R is12、R13、R14Each independently selected from H, C with or without substituents1-8With or without substituents C1-8And C with or without substituents1-8E is an integer between 0 and 3 (e.g., 1, 2, or 3);
w is absent or selected from O, NR17、-X2C(＝O)X3、-X2S(＝O)gX3; wherein R is17Is H, C with or without substituents1-8With or without substituents C1-8Cycloalkyl, with or without substituents C1-8The heterocyclic hydrocarbon group of (a); wherein X2 and X3 are independently deleted or selected from O, S, NR18(ii) a Wherein g is an integer from 0 to 2; wherein R is18Is H, C with or without substituents1-8With or without substituents C1-8Cycloalkyl, with or without substituents C1-8The heterocyclic hydrocarbon group of (a);
y is (CR)22R23)h、CHX4(CR22R23)h、CX4＝CH(CR22R23)hOr (CR)22R23)h(ii) a Wherein h is an integer between 0 and 30; wherein R is22、R23Each independently selected from H, cyano, hydroxy, amino, C with or without substituents1-8With or without substituents C1-8Cycloalkyl, with or without substituents C1-8A heterocyclic hydrocarbon group of (A), C with or without substituents1-8Hydrocarbyloxy groups of (a); wherein X4 ═ H, halogen, cyano, nitro, hydroxy, with or without substituent C1-8Hydrocarbyloxy, with or without substituents C1-8Alkoxycarbonyl, with or without substituents C1-8Amino, with or without substituents C1-8Ester group, with or without substituents C1-8Aminocarbonyl groupRadical, with or without substituents C1-8Hydrocarbyl, with or without substituents C1-8Cycloalkyl, with or without substituents C1-8A heterocyclic hydrocarbon group;
z is (CR)24R25)i、CHX5(CR24R25)i、CX5＝CH(CR24R25)iOr C ≡ C (CR)24R25)i(ii) a Wherein i is an integer between 0 and 30; wherein R is24、R25Each independently selected from H, cyano, hydroxy, amino, C with or without substituents1-8With or without substituents C1-8Cycloalkyl, with or without substituents C1-8Heterocycloalkyl radicals, with or without substituents C1-8A hydrocarbyloxy group; wherein X5 ═ H, halogen, cyano, nitro, hydroxy, with or without substituent C1-8With or without substituents C1-8Alkoxycarbonyl, with or without substituents C1-8Amino, with or without substituents C1-8Ester group, with or without substituents C1-8Aminocarbonyl, with or without substituents C1-8Hydrocarbyl, with or without substituents C1-8Cycloalkyl, with or without substituents C1-8A heterocyclic hydrocarbon group;
b is absent or selected from O, C ═ O, S, NR15、-NR15C(＝O)-、-C(＝O)NR15-、-C(＝O)O-、OC(＝O)O-、-NR15C(＝O)O-、-OC(＝O)NR15-、-NR15C(＝O)NR16-, C with or without substituents1-12With or without substituents C1-12And C with or without substituents1-12The heterocyclic hydrocarbon group of (a); wherein R is15、R16Each independently selected from H, C with or without substituents1-8With or without substituents C1-8And C with or without substituents1-8The heterocyclic hydrocarbon group of (a);
x is selected from CR19R20、C(＝O)、S(＝O)、SO2、NR21(ii) a Wherein R is19、R20Each independently selected from H, cyano, hydroxy, amino, C with or without substituents1-8With or without substituents C1-8Cycloalkyl, with or without substituents C1-8A heterocyclic hydrocarbon group of (A), C with or without substituents1-8Hydrocarbyloxy groups of (a); wherein R is21Selected from H, C with or without substituents1-8With or without substituents C1-8Cycloalkyl, with or without substituents C1-8The heterocyclic hydrocarbon group of (a);
R1、R6、R10each independently selected from H, C with or without substituents1-8Hydrocarbon group, cycloalkyl group with or without substituent, heterocycloalkyl group with or without substituent, C with or without substituent1-6An acyl group;
R2、R5each independently selected from: hydrogen, OR33、NR34R35Cyano, halogen, C with or without substituents1～8Hydrocarbon group, cycloalkyl group with or without substituent, heterocycloalkyl group with or without substituent, C with or without substituent1-6Acyl, amido with or without substituents; wherein R is33、R34、R35Each independently selected from H, C with or without substituents1～8A cycloalkyl group with or without substituents, a heterocycloalkyl group with or without substituents;
R3、R7、R8、R9each independently selected from: H. OR (OR)27、NR28R29Cyano, halogen, nitro, C with or without substituents1-8A hydrocarbon group, a cycloalkyl group with or without a substituent, a heterocycloalkyl group with or without a substituent, X6S (═ O)kR30、X6C(＝O)R31(ii) a Wherein k is an integer between 0 and 2; wherein R is27，R28，R29，R30，R31Each independently selected from H, with or withoutC with substituents1～8Hydrocarbyl, cycloalkyl, heterocycloalkyi; wherein X6 is absent or selected from O, S, NR32(ii) a Wherein R is32Is H, C with or without substituents1-8A cycloalkyl group with or without substituents, and a heterocycloalkyl group with or without substituents;
R4selected from H, cyano, carboxyl, C with or without substituents1-8A hydrocarbon group of (a), a hydrocarbyloxycarbonyl group with or without a substituent group;
a is an integer between 0 and 5 (e.g., 1, 2, 3, 4, 5);
b is an integer between 0 and 3 (e.g., 1, 2, 3);
c is an integer between 0 and 30 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9);
d is an integer between 0 and 9 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9).
In another preferred embodiment, a is absent; w is X2C (═ O) X3 where X2 is NR18And X3 is absent, or X3 is NR18And X2 is absent; y is (CR)22R23)hWherein R is22、R23Each independently selected from H, hydroxy, C with or without substituents1-4H is an integer between 1 and 6; z is (CR)24R25)iWherein R is24、R25Each independently selected from H, hydroxy, C with or without substituents1-4I is an integer between 1 and 6; c is 0.
In another preferred embodiment, a is absent; w is absent or is O; y is (CR)22R23)hWherein R is22、R23Each independently selected from H, hydroxy, C with or without substituents1-4H is an integer between 0 and 3; b is O; z is (CR)24R25)iWherein R is24、R25Each independently selected from H, hydroxy, C with or without substituents1-4I is an integer between 0 and 3; c is an integer between 1 and 6.
In another preferred embodiment, a is C (═ O) X1, which isWherein X1 is absent or selected from (CR)12R13)eO, and (CR)12R13)eS, wherein e is an integer between 0 and 2, R12、R13、R14Each independently is hydrogen or C1-4Alkyl groups of (a); w is NR17Wherein R is17Is H, or C with or without substituents1-4A hydrocarbon group of (a); y is (CR)22R23)hWherein R is22、R23Each independently selected from H, hydroxy, C with or without substituents1-4H is an integer between 0 and 3; z is (CR)24R25)iWherein R is24、R25Each independently selected from H, hydroxy, C with or without substituents1-4I is an integer between 0 and 3; b is O; c is an integer between 1 and 4.
In another preferred embodiment, A is SO2X1, wherein X1 is absent or selected from O, and S; w is O; y is (CR)22R23)hWherein R is22、R23Each independently selected from H, hydroxy, C with or without substituents1-4H is an integer between 1 and 6; z is (CR)24R25)iWherein R is24、R25Each independently selected from H, hydroxy, C with or without substituents1-4I is an integer between 0 and 3; c is 0.
In another preferred embodiment, a is absent; w is NR17Wherein R is17Is H, or C with or without substituents1-4A hydrocarbon group of (a); y is (CR)22R23)hWherein R is22、R23Each independently selected from H, hydroxy, C with or without substituents1-4H is an integer between 0 and 3; z is (CR)24R25)iWherein R is24、R25Each independently selected from H, hydroxy, C with or without substituents1-4I is an integer between 0 and 4; b is O; c is an integer between 1 and 6.
In another preferred embodiment, a is absent; deletion of W;y is (CR)22R23)hWherein R is22、R23Each independently selected from H, hydroxy, C with or without substituents1-4H is an integer between 0 and 3; z is (CR)24R25)iWherein R is24、R25Each independently selected from H, hydroxy, C with or without substituents1-4I is an integer between 0 and 3; b is O; c is an integer between 1 and 10 (preferably between 1 and 6).
In another preferred embodiment, any of the substituents is selected from the group consisting of: halogen, unsubstituted or halogenated C1-C6 alkyl, unsubstituted or halogenated C1-C6 alkoxy, unsubstituted or halogenated C2-C6 alkoxyalkyl, unsubstituted or halogenated C3-C8 cycloalkyl, unsubstituted or halogenated C2-C6 alkylcarbonyl, unsubstituted or halogenated C1-C6 alkylene-hydroxy, unsubstituted or C1-C6 alkyl-substituted amine.
In another preferred embodiment, in formula I,
represents a single bond.
In another preferred example, X is C (═ O).
In another preferred embodiment, R1Selected from: H. and C with or without substituents1-4An alkyl group.
In another preferred embodiment, R2、R5Each independently selected from: hydrogen, and C with or without substituents1-4An alkyl group.
In another preferred embodiment, R3Selected from: hydrogen, and C with or without substituents1-4An alkyl group.
In another preferred embodiment, R6Selected from: hydrogen, C with or without substituents1-4Alkyl, OR29Wherein R is29Selected from H, C with or without substituents1-6An alkyl group.
In another preferred embodiment, R7Selected from: hydrogen, C with or without substituents1-4Alkyl, and NR28R29Wherein R is28R29Is H, or C with or without substituents1-4A hydrocarbon group of (1).
In another preferred embodiment, R8Selected from: hydrogen, halogen, and C with or without substituents1-4An alkyl group.
In another preferred embodiment, R9Selected from: hydrogen, halogen, and C with or without substituents1-4An alkyl group.
In another preferred embodiment, R10Selected from: hydrogen, halogen, cyano, nitro, and C with or without substituents1-4An alkyl group.
In another preferred embodiment, R4Selected from H, cyano, C with or without substituents1-6An alkyl group.
In a second aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the first aspect, or a pharmaceutically acceptable salt, prodrug thereof, and a pharmaceutically acceptable carrier.
In another preferred embodiment, the effective amount refers to a therapeutically effective amount or an inhibitory effective amount, preferably 0.01 to 99.99%.
In another preferred embodiment, the pharmaceutical composition further comprises one or more additional antineoplastic agents.
In another preferred embodiment, the pharmaceutical composition is for use in degrading JAK 3.
In another preferred embodiment, the pharmaceutical composition is used for treating diseases related to the activity or expression amount of JAK 3.
In a third aspect of the invention, there is provided the use of a compound according to the first aspect of the invention for:
(a) preparing a medicament for treating diseases related to the activity or expression amount of JAK 3;
(b) preparing a JAK3 targeted degradation agent;
(c) non-therapeutically degrading JAK3 in vitro;
(d) non-therapeutically inhibiting tumor cell proliferation in vitro; and/or
(e) Treating diseases associated with the activity or expression level of JAK 3.
In another preferred embodiment, the disease associated with JAK3 activity or expression is a neoplastic or autoimmune disease.
In another preferred embodiment, the disease associated with JAK3 activity or expression is selected from the group consisting of: organ transplant rejection, xenograft rejection, lupus erythematosus, multiple sclerosis, rheumatoid arthritis, psoriasis, cancer, asthma, atopic dermatitis, type I diabetes and diabetic complications, autoimmune thyroid disorders, ulcerative colitis, crohn's disease, alzheimer's disease, leukemia, lymphoma, multiple myeloma, alopecia areata, vitiligo, and the like.
In a fourth aspect of the invention, there is provided a process for the preparation of a compound of formula I as described in the first aspect of the invention, comprising the steps of:
(a) reacting a compound shown in a formula IV with a compound shown in a formula II in an inert solvent to obtain a compound shown in a formula I;
in the above formulae, each group is as defined above, M1Is a leaving group.
In another preferred example, the method further comprises the steps of:
(b) reacting a compound of formula III with a compound of formula V in an inert solvent to give a compound of formula II, M1、M2Is a leaving group.
In a fifth aspect of the invention, there is provided a method of degrading JAK3, comprising the steps of: administering to a subject an effective amount of a compound of formula I as described in the first aspect of the invention or a pharmaceutically acceptable salt thereof, or administering to a subject an inhibitory effective amount of a pharmaceutical composition as described in the fourth aspect of the invention.
In another preferred embodiment, said degradation is non-therapeutic in vitro.
In another preferred embodiment, when an effective amount of a compound of formula I according to the first aspect of the invention or a pharmaceutically acceptable salt thereof is administered to a subject, the inhibitory effective amount is 0.001-500nmol/L, preferably 0.01-200 nmol/L.
In a sixth aspect of the present invention, there is provided a method of treating a disease associated with JAK3 activity or expression, the method comprising: administering to a subject a therapeutically effective amount of a compound of formula I according to the first aspect of the invention, or a pharmaceutical composition according to the fourth aspect of the invention.
In another preferred embodiment, the subject is a mammal; preferably, the mammal is a human.
In another preferred embodiment, the disease associated with JAK3 activity or expression is a neoplastic or autoimmune disease.
In another preferred embodiment, the disease associated with JAK3 activity or expression is selected from the group consisting of: organ transplant rejection, xenograft rejection, lupus erythematosus, multiple sclerosis, rheumatoid arthritis, psoriasis, cancer, asthma, atopic dermatitis, type I diabetes and diabetic complications, autoimmune thyroid disorders, ulcerative colitis, crohn's disease, alzheimer's disease, leukemia, lymphoma, multiple myeloma, alopecia areata, vitiligo, and the like.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be reiterated herein, but to the extent of space.
Detailed Description
The inventors of the present invention have made extensive and intensive studies to prepare a compound having a structure represented by formula I, and found that it has JAK3 degradation activity. And the compound can generate degradation effect on JAK3 at an extremely low concentration, and has extremely excellent activity, so that the compound can be used for treating diseases related to the activity or expression level of JAK3, such as tumors. The present invention has been completed based on this finding.
The invention provides a novel compound and application thereof in degrading tyrosine protein kinase JAK 3. The compounds of the present invention are capable of degrading JAK3, and are useful as JAK3 degradants having a dual role in immunomodulation, and for the treatment of diseases in mammals such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, keratoconjunctivitis sicca, and Crohn's disease.
Term(s) for
In the present invention, the term "C1-8The hydrocarbyl group means a functional group containing only carbon and hydrogen atoms, wherein the number of carbon atoms is 1 to 8. The hydrocarbyl group can be regarded as a radical remaining after the corresponding hydrocarbon loses one hydrogen atom, and can be an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group or the like; the structure can be straight chain, branched chain or cyclic; may be aliphatic or aromatic.
The term "C1-6The "alkyl group" means a straight or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, or the like.
The term "alkoxy" as used herein includes O-alkyl, wherein "alkyl" is as defined above.
The term "halo" as used herein, unless otherwise indicated, includes fluoro, chloro, bromo or iodo.
The compounds of the present invention may contain double bonds. When containing such double bonds, the compounds of the present invention exist in cis, trans, or mixtures thereof.
Halogen as used herein includes fluorine, chlorine, bromine and iodine.
Unless otherwise indicated, alkyl groups and the alkyl portion of alkoxy groups referred to herein may be straight chain, branched chain or cyclic.
In the present invention, the term "cycloalkyl group" refers to a functional group containing both carbon and hydrogen atoms. Including cycloalkyl, cycloalkenyl (containing at least one carbon-carbon double bond), and aryl. They may be monocyclic, bicyclic and polycyclic. They may be spiro or fused rings.
In the present invention, the term "heterocyclic hydrocarbon group" means a functional group containing carbon, hydrogen and at least one heteroatom other than carbon and hydrogen. Including heterocycloalkyl, heterocycloalkenyl (containing at least one carbon-carbon double bond), and heteroaryl. One or more of the ring-forming atoms in the ring is a heteroatom. The heteroatoms may be O, N and S atoms, and various combinations thereof. They may be monocyclic, bicyclic and polycyclic. They may be spiro or fused rings.
In the present invention, the term "substituent" includes, but is not limited to, fluorine, chlorine, bromine, cyano, hydroxyl, amino, C1-6Hydrocarbyloxy, C1-6Halogenated hydrocarbon group, C1-6Acyl radical, C1-6A sulfonyl group.
The term "hydrocarbyloxy" as used herein refers to an O-hydrocarbyl group, wherein "hydrocarbyl" is as defined above.
The term "alkoxycarbonyl" as used herein refers to a C (═ O) O-hydrocarbyl group, where "hydrocarbyl" is as defined above.
The term "amine" as used herein refers to N (H or hydrocarbyl 1) (H or hydrocarbyl 2), wherein "hydrocarbyl" is as defined above.
The term "aminocarbonyl" as used herein refers to C (═ O) -amine groups, where "amine groups" are as defined above.
The term "amido", as used herein, refers to an N (H or hydrocarbyl) -C (═ O) -hydrocarbyl group, where the "hydrocarbyl group" is as defined above.
As used herein, the terms "comprising," "including," or "including" mean that the various ingredients may be used together in a mixture or composition of the invention. Thus, the terms "consisting essentially of and" consisting of are encompassed by the term "comprising.
In the present invention, the term "pharmaceutically acceptable" ingredient refers to a substance that is suitable for use in humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response), i.e., at a reasonable benefit/risk ratio.
In the present invention, the term "effective amount" refers to an amount of a therapeutic agent that treats, alleviates, or prevents a target disease or condition, or an amount that exhibits a detectable therapeutic or prophylactic effect. The precise effective amount for a subject will depend upon the size and health of the subject, the nature and extent of the disorder, and the therapeutic agent and/or combination of therapeutic agents selected for administration. Therefore, it is not useful to specify an exact effective amount in advance. However, for a given condition, the effective amount can be determined by routine experimentation and can be determined by a clinician.
Herein, unless otherwise specified, the term "substituted" means that one or more hydrogen atoms on a group are replaced with a substituent selected from the group consisting of: halogen, unsubstituted or halogenated C1-6Alkyl, unsubstituted or halogenated C2-6Acyl, unsubstituted or halogenated C1-6Alkyl-hydroxy.
Unless otherwise specified, all occurrences of a compound in the present invention are intended to include all possible optical isomers, such as a single chiral compound, or a mixture of various chiral compounds (i.e., a racemate). In all compounds of the present invention, each chiral carbon atom may optionally be in the R configuration or the S configuration, or a mixture of the R configuration and the S configuration.
As used herein, the term "compounds of the invention" refers to compounds of formula I. The term also includes various crystalline forms, pharmaceutically acceptable salts, hydrates or solvates of the compounds of formula I.
As used herein, the term "pharmaceutically acceptable salt" refers to a salt of a compound of the present invention with an acid or base that is suitable for use as a pharmaceutical. Pharmaceutically acceptable salts include inorganic and organic salts. One preferred class of salts is that formed by reacting a compound of the present invention with an acid. Suitable acids for forming the salts include, but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, etc., organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, phenylmethanesulfonic acid, benzenesulfonic acid, etc.; and acidic amino acids such as aspartic acid and glutamic acid.
Compounds and pharmaceutically acceptable salts thereof
The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof;
wherein:
-represents a single bond;
a is absent or selected from C (═ O), C (═ O) X1, SOX1, SO2X1, C with or without substituents1-8Hydrocarbyl, C with or without substituents1-8Cycloalkyl group, and C with or without substituent1-8A heterocyclic hydrocarbon group; wherein X1 is absent or selected from (CR)12R13)eO、(CR12R13)eS and NR14(ii) a Wherein R is12、R13、R14Each independently selected from H, C with or without substituents1-8With or without substituents C1-8And C with or without substituents1-8E is an integer between 0 and 3;
w is absent or selected from O, NR17、-X2C(＝O)X3、-X2S(＝O)gX3; wherein R is17Is H, C with or without substituents1-8With or without substituents C1-8Cycloalkyl, with or without substituents C1-8The heterocyclic hydrocarbon group of (a); wherein X2 and X3 are independently deleted or selected from O, S, NR18(ii) a Wherein g is an integer from 0 to 2; wherein R is18Is H, C with or without substituents1-8With or without substituents C1-8Cycloalkyl, with or without substituents C1-8The heterocyclic hydrocarbon group of (a);
y is (CR)22R23)h、CHX4(CR22R23)h、CX4＝CH(CR22R23)hOr (CR)22R23)h(ii) a Wherein h is an integer between 0 and 30; wherein R is22、R23Each independently selected from H, cyano, hydroxy, amino, C with or without substituents1-8With or without substituents C1-8Cycloalkyl, with or without substituents C1-8A heterocyclic hydrocarbon group of (A), C with or without substituents1-8Hydrocarbyloxy groups of (a); wherein X4 ═ H, halogen, cyano, nitro, hydroxy, with or without substituent C1-8Hydrocarbyloxy, with or without substituents C1-8Alkoxycarbonyl, with or without substituents C1-8Amino, with or without substituents C1-8Ester group, with or without substituents C1-8Aminocarbonyl, with or without substituents C1-8Hydrocarbyl, with or without substituents C1-8Cycloalkyl, with or without substituents C1-8A heterocyclic hydrocarbon group;
z is (CR)24R25)i、CHX5(CR24R25)i、CX5＝CH(CR24R25)iOr C ≡ C (CR)24R25)i(ii) a Wherein i is an integer between 0 and 30; wherein R is24、R25Each independently selected from H, cyano, hydroxy, amino, C with or without substituents1-8With or without substituents C1-8Cycloalkyl, with or without substituents C1-8Heterocycloalkyl radicals, with or without substituents C1-8A hydrocarbyloxy group; wherein X5 ═ H, halogen, cyano, nitro, hydroxy, with or without substituent C1-8With or without substituents C1-8Alkoxycarbonyl, with or without substituents C1-8Amino, with or without substituents C1-8Ester group, with or without substituents C1-8Aminocarbonyl, with or without substituents C1-8Hydrocarbyl, with or without substituents C1-8Cycloalkyl, with or without substituents C1-8A heterocyclic hydrocarbon group;
b is absent or selected from O, C ═ O, S, NR15、-NR15C(＝O)-、-C(＝O)NR15-、-C(＝O)O-、OC(＝O)O-、-NR15C(＝O)O-、-OC(＝O)NR15-、-NR15C(＝O)NR16-, C with or without substituents1-12With or without substituents C1-12And C with or without substituents1-12The heterocyclic hydrocarbon group of (a); wherein R is15、R16Each independently selected from H, C with or without substituents1-8With or without substituents C1-8And C with or without substituents1-8The heterocyclic hydrocarbon group of (a);
x is selected from CR19R20、C(＝O)、S(＝O)、SO2、NR21(ii) a Wherein R is19、R20Each independently selected from H, cyano, hydroxy, amino, C with or without substituents1-8With or without substituents C1-8Cycloalkyl, with or without substituents C1-8A heterocyclic hydrocarbon group of (A), C with or without substituents1-8Hydrocarbyloxy groups of (a); wherein R is21Selected from H, C with or without substituents1-8With or without substituents C1-8Cycloalkyl, with or without substituents C1-8The heterocyclic hydrocarbon group of (a);
R1、R6、R10each independently selected from H, C with or without substituents1-8Hydrocarbon group, cycloalkyl group with or without substituent, heterocycloalkyl group with or without substituent, C with or without substituent1-6An acyl group;
R2、R5each independently selected from: hydrogen, OR33、NR34R35Cyano, halogen, C with or without substituents1～8Hydrocarbon group, cycloalkyl group with or without substituent, heterocycloalkyl group with or without substituent, C with or without substituent1-6Acyl, amido with or without substituents; wherein R is33、R34、R35Each independently selected from H, with or without substitutionC of radical1～8A cycloalkyl group with or without substituents, a heterocycloalkyl group with or without substituents;
R3、R7、R8、R9each independently selected from: H. OR (OR)27、NR28R29Cyano, halogen, nitro, C with or without substituents1-8A hydrocarbon group, a cycloalkyl group with or without a substituent, a heterocycloalkyl group with or without a substituent, X6S (═ O)kR30、X6C(＝O)R31(ii) a Wherein k is an integer between 0 and 2; wherein R is27，R28，R29，R30，R31Each independently selected from H, C with or without substituents1～8Hydrocarbyl, cycloalkyl, heterocycloalkyi; wherein X6 is absent or selected from O, S, NR32(ii) a Wherein R is32Is H, C with or without substituents1-8A cycloalkyl group with or without substituents, and a heterocycloalkyl group with or without substituents;
R4selected from H, cyano, carboxyl, C with or without substituents1-8A hydrocarbon group of (a), a hydrocarbyloxycarbonyl group with or without a substituent group;
a is an integer between 0 and 5 (e.g., 1, 2, 3, 4, 5);
b is an integer between 0 and 3 (e.g., 1, 2, 3);
c is an integer between 0 and 30 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9);
d is an integer between 0 and 9 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9).
The integer described herein may be 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9, unless otherwise specified.
In a preferred embodiment of the invention, the compound is selected from the group consisting of:
the compound package of the present invention may form pharmaceutically acceptable salts with inorganic acids, organic acids or bases. The inorganic acid includes but is not limited to hydrochloric acid, hydrobromic acid, nitric acid, perchloric acid, sulfuric acid or phosphoric acid, etc.; such organic acids include, but are not limited to, methanesulfonic acid, trifluoromethanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, fumaric acid, oxalic acid, acetic acid, maleic acid, ascorbic acid, lactic acid, tartaric acid, malonic acid, glycolic acid, succinic acid, propionic acid, and the like; the base includes, but is not limited to, inorganic salts and amines.
The term pharmaceutically acceptable salts refers to those salts which are, according to medical judgment, suitable for use in contact with the tissues of humans and mammals without excessive toxicity, irritation, allergic response, and the like. Pharmaceutically acceptable salts are well known in the art.
The invention also encompasses pharmaceutical compositions containing prodrugs of compounds of formula I. Prodrugs include compounds wherein the precursor molecule is covalently bonded to a free carboxyl, hydroxyl, amino or amine group of the compound of formula I via a carbonate, carbamate, amide, alkyl ester, phosphate, phosphoramidate linkage.
Preparation of the Compounds
Preparation method
The process for the preparation of the compounds of formula I according to the invention is described in more detail below, but these particular processes do not limit the invention in any way. The compounds of the present invention may also be conveniently prepared by optionally combining various synthetic methods described in the present specification or known in the art, and such combinations may be readily carried out by those skilled in the art to which the present invention pertains.
The following reaction scheme illustrates the preparation of the compounds of the present invention. Unless otherwise indicated, A, B, W, Y, Z, X, a, B, c, d, R in the reaction schemes and discussion that follows1、R2、R3、R4、R5、R6、R7、R8、R9、R10As defined above.
In general, compounds of formula I can be obtained from formula III as described in the following scheme:
in compound II, when W is an ether, it can be prepared by direct nucleophilic substitution of formula III (W1 ═ OH) with an intermediate containing a leaving group under the action of a base, or by reaction with an alcohol using a mitsunobu reaction; when W is ester, carbamate (NHCO)2) When the compound is prepared, the compound can be prepared by reacting formula III (W1 ═ OH) with acyl chloride, activated ester (amide), carboxylic acid and isocyanate under the action of alkali; when W is an amine, formula III (W1 ═ NH) can be used2) Direct nucleophilic substitution with an intermediate containing a leaving group under the action of a base can also be prepared by using a compound of formula III (W1 ═ NH)2) (ii) reductive amination with aldehydes/ketones; when W is an amide, alkoxycarbonylamine (OCONH), or urea, formula III (W1 ═ NH) can be used2) Reacting with corresponding acyl chloride, activated ester (amide), carboxylic acid and isocyanate under the action of alkali.
In compound I, when A is linked to the nitrogen atom by a C-N bond, it can be prepared by direct substitution or reductive amination; when A is attached to the nitrogen atom by means of an amide, urea, carbamate, sulfonamide, thioamide, it can be prepared from the corresponding acid chlorides, activated esters (amides), carboxylic acids, isocyanates, sulfonyl chlorides, sulfuryl chlorides.
In general, depending on the nature of the linkages A and W, compounds I may also be obtained by linking formula IV to an intermediate chain and then reacting with formula III. The chemical synthesis method is the same as that described above.
The compounds of formula III, IV can be obtained by known synthetic methods or readily obtained by commercial purchase.
Use of compounds of formula I
The compounds of formula I may be used for one or more of the following uses:
(a) preparing a medicament for treating diseases related to the activity or expression amount of JAK 3;
(b) preparing a JAK3 targeted degradation agent;
(c) non-therapeutically degrading JAK3 in vitro;
(d) non-therapeutically inhibiting tumor cell proliferation in vitro; and/or
(e) Treating diseases related to the activity or expression level of JAK3 (such as autoimmune diseases).
In another preferred embodiment, the disease associated with JAK3 activity or expression is organ transplant rejection, xenotransplantation, lupus erythematosus, multiple sclerosis, rheumatoid arthritis, psoriasis, cancer, asthma, atopic dermatitis, type I diabetes and diabetic complications, autoimmune thyroid disorders, ulcerative colitis, crohn's disease, alzheimer's disease, leukemia, lymphoma, multiple myeloma, alopecia areata, vitiligo, and the like.
The compounds of formula I of the present invention are useful for preparing a pharmaceutical composition comprising: (i) an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable carrier.
In another preferred embodiment, the effective amount refers to a therapeutically effective amount or an inhibitory effective amount.
The compounds of formula I of the present invention may also be used in methods of inhibiting or degrading bujak 3, either in vitro non-therapeutic or therapeutic inhibition.
In another preferred embodiment, when an inhibitory effective amount of a compound of formula I of the present invention or a pharmaceutically acceptable salt thereof is administered to a subject, said inhibitory effective amount is 0.001-500nmol/L, preferably 0.01-200 nmol/L.
In particular, the present invention also provides a method of treating a disease associated with JAK3 activity or expression comprising: administering to the subject a therapeutically effective amount of a compound of formula I, or said pharmaceutical composition comprising a compound of formula I as an active ingredient.
Pharmaceutical compositions and methods of administration
The compound can obviously degrade JAK3 so as to play a role in inhibiting JAK3, so that the compound and various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates thereof, and a pharmaceutical composition containing the compound as a main active ingredient can be used for treating, preventing and relieving diseases related to the activity or expression amount of JAK 3. According to the prior art, the compounds of the present invention are useful in the treatment of diseases including tumors and the like.
The pharmaceutical composition of the present invention comprises the compound of the present invention or a pharmacologically acceptable salt thereof in a safe and effective amount range and a pharmacologically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000mg of a compound of the invention per dose, more preferably, 5-200mg of a compound of the invention per dose. Preferably, said "dose" is a capsule or tablet.
"pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. By "compatible" is meant herein that the components of the composition are capable of intermixing with and with the compounds of the present invention without significantly diminishing the efficacy of the compounds. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), and the like
) Wetting agents (e.g., sodium lauryl sulfate), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like.
The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, for example, glycerol; (d) disintegrating agents, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) absorption accelerators, e.g., quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glycerol monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shells such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be delayed in release in a certain part of the digestive tract. Examples of embedding components which can be used are polymeric substances and wax-like substances. If desired, the active compound may also be in microencapsulated form with one or more of the above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly employed in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, in particular, cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of such materials and the like.
In addition to these inert diluents, the compositions may also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols and suitable mixtures thereof.
Dosage forms for topical administration of the compounds of the present invention include ointments, powders, patches, sprays, and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required if necessary.
The compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
When the pharmaceutical composition is used, a safe and effective amount of the compound of the present invention is suitable for mammals (such as human beings) to be treated, wherein the administration dose is a pharmaceutically-considered effective administration dose, and for a human body with a weight of 60kg, the daily administration dose is usually 1 to 2000mg, preferably 5 to 500 mg. Of course, the particular dosage will depend upon such factors as the route of administration, the health of the patient, and the like, and is within the skill of the skilled practitioner.
The main advantages of the invention include:
1. provides a compound shown as a formula I.
2. The JAK3 degrading agent with a novel structure and preparation and application thereof are provided, and the inhibitor can degrade JAK3 at an extremely low concentration.
3. Pharmaceutical compositions for treating diseases associated with JAK3 activity are provided.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out under conventional conditions or conditions recommended by the manufacturers. Unless otherwise indicated, percentages and parts are percentages and parts by weight.
EXAMPLE 1 preparation of Compound 3
The first step is as follows:
2.14g of 6-bromohexanoyl chloride and 1.37g of pomalidomide are dissolved in 50ml of THF (tetrahydrofuran), and the mixture is stirred and refluxed for 8 hours, cooled to room temperature, concentrated and dried in vacuum at 40 ℃ to obtain 2.19g of the compound (1). MS (ESI) 450[ M + H]+。
The second step is that:
dissolving 1g of compound (1), 1.28g of compound (2) and 2.6g of DIPEA (N, N-diisopropylethylamine) in 50ml of DMF (N, N-dimethylformamide), stirring at 80 ℃ for 6h, cooling to room temperature, concentrating, and performing column chromatography to obtain 810mg of compound (3), yield: 65.6 percent. MS (ESI) 615[ M + H]+。1H NMR(400MHz,CD3OD)δ8.61(d,J＝8Hz,1H),8.11(s,1H),7.72(m,1H),7.54(d,J＝8Hz,1H),7.10(d,J＝4Hz,1H),6.63(s,1H),5.14(dd,J＝12,4Hz,1H),3.48(br,3H),3.37(s,1H),2.50-3.10(m,10H),2.32(m,1H),2.16(m,1H),1.25-2.00(m,9H),1.03(d,J＝8Hz,3H)。
EXAMPLE 2 preparation of Compound 7
The first step is as follows:
100mg of 4-hydroxythalidomide, 96mg of triethylene glycol monobenzyl ether and 100mg of triphenylphosphine were dissolved in 10ml of anhydrous THF, and 95mg of DIAD (diisopropyl azodicarboxylate) was added dropwise thereto and reacted at room temperature for 2 hours. THF was removed under reduced pressure, and column chromatography was performed to purify the residue to give 110mg of the compound (4). MS (ESI) 497[ M + H]+。
The second step is that:
100mg of compound (4) and 100mg of 10% Pd-C were added to 10ml of methanol, and the mixture was hydrogenated at room temperature overnight. Filtration, concentration of the filtrate and purification of the residue by column chromatography gave 40mg of compound (5). MS (ESI) 407[ M + H]+。
The third step:
30mg of the compound (5) was dissolved in 5ml of methylene chloride, and 47mg of Dess-martin oxidant was added thereto to conduct a reaction at room temperature for 3 hours. Adding NaHCO3Saturated aqueous solution and Na2S2O3Stirring for 5min to obtain organic layer, and treating with anhydrous Na2S2O3Drying and concentrating to dryness to obtain the compound (6) which is directly used for the next reaction.
After dissolving Compound (6) in 7ml of methylene chloride, 36mg of the starting Material (2) and NaBH (OAc) were added323mg, reacted at room temperature overnight, then dichloromethane was distilled off under reduced pressure, and purified by column chromatography to give Compound (7), 20mg. MS (ESI):634[ M + H ]]+。1H NMR (hydrochloride, 400MHz, D)2O)δ8.09(d,J＝1.6Hz,1H),7.45-7.62(m,1H),7.18(dd,J＝12.0,7.2Hz,1H),7.07(m,2H),6.54-6.70(m,1H),4.90-5.08(m,2H),4.12(m,2H),3.30-3.85(m,14H),3.20(s,3H),2.73(m,2H),2.42(m,2H),2.09(m,2H),1.73(m,1H),1.00(d,J＝8.0Hz,3H)。
EXAMPLE 3 preparation of Compound 10
The first step is as follows:
benzyl 2- (2- (2-bromoethoxy) ethoxy) acetate 174mg, potassium carbonate 100mg, potassium iodide 20mg and pomalidomide 100mg were added to 20ml of DMF (N, N-dimethylformamide) and reacted at 80 ℃ overnight. The reaction solution was purified by column chromatography to give 113mg of the compound (8). MS (ESI) 510[ M + H]+。
The second step is that:
100mg of Compound (8) and 10% Pd-C100mg were added to 10ml of methanol, and the mixture was hydrogenated at room temperature overnight. Filtration, concentration of the filtrate and purification of the residue by column chromatography gave 73mg of compound (9). MS (ESI negative ion) 418[M-H]-。
The third step:
50mg of the compound (9) and 30mg of the starting material (2) were dissolved in 5ml of methylene chloride, and 20mg of HOBt (1-hydroxybenzotriazole) and 40mg of EDC (1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride) were added to the solution to conduct a reaction at room temperature overnight. Removing dichloromethane by evaporation under reduced pressure, and purifying by column chromatography to obtain compound (10), 50mg. MS (ESI):647[ M + H ]]+。1H NMR(400MHz,CDCl3)δ10.63(br,1H),9.84(br,1H),8.22(d,J＝1.2Hz,1H),7.43(t,J＝7.6Hz,1H),7.06(dd,J＝7.2,1.2Hz,1H),6.97(d,J＝2.8Hz,1H),6.82(d,J＝8.4Hz,1H),6.51(d,J＝3.6Hz,1H),6.42(m,1H),5.12(br,1H),4.91(m,1H),4.55(br,2H),3.89(m,4H),3.64(s,3H),3.51(br,2H),3.38(m,3H),2.50-3.01(m,6H),2.25(br,1H),2.10(m,1H),1.86(br,1H),1.64(br,1H),0.96(d,J＝6.8Hz,3H)。
EXAMPLE 4 preparation of Compound 13
The first step is as follows:
200mg of the starting material (2) was dissolved in 20ml of methylene chloride, and 100mg of triethylamine and 180mg of 5-benzyloxypentanesulfonyl chloride were added to the solution to conduct a reaction at room temperature overnight. The solvent was distilled off under reduced pressure, and column chromatography was performed to purify the residue to obtain 187mg of compound (11). MS (ESI) 486[ M + H]+。
The second step is that:
180mg of compound (11) and 180mg of 10% Pd-C were added to 20ml of methanol, and the mixture was hydrogenated at room temperature overnight. Filtering, concentrating the filtrate, and purifying by column chromatography to obtain compound (12)134mg, MS (ESI):396[ M + H]+。
The third step:
50mg of 4-hydroxythalidomide, 50mg of triphenylphosphine and 50mg of compound (12) were dissolved in 5ml of anhydrous tetrahydrofuran, and 50mg of DIAD (diisopropyl azodicarboxylate) was added dropwise and reacted at room temperature for 3 hours. The tetrahydrofuran was removed under reduced pressure, and column chromatography was performed to purify the residue to obtain 33mg of the compound (13). MS (ESI) 652[ M + H]+。1H NMR (hydrochloride, 400MHz, D)2O)δ8.11(d,J＝2.0Hz,1H),7.43-7.61(m,1H),7.20(dd,J＝11.6,6.8Hz,1H),7.08(m,2H),6.60-6.71(m,1H),5.02(m,2H),4.54(m,1H),4.02(m,2H),3.85(m,2H),3.18(s,3H),2.72-3.12(m,4H),2.15-2.50(m,4H),1.28-2.06(m,9H),0.96(d,J＝7.6Hz,3H)。
The following compounds were prepared by a method analogous to examples 2, 3:
the following compounds were prepared by a method analogous to example 2:
example 4 Western blot to detect JAK3 protein degrading Activity of Compounds
Cell lines: jurkat cell line was cultured in RPMI1640 containing 10% calf serum at 37 ℃ in 5% CO2And culturing in an incubator with saturated humidity.
A DMSO control group and a compound dry group (10 mu M) are arranged, cells are collected after 6 hours of treatment, 100 mu L of precooled cell lysate is added, the cells are lysed for 30min on ice, total cell protein is extracted, and the protein concentration is determined and quantified by a bicinchoninic acid (BCA) method. Preparing gel conventionally, loading, performing electrophoresis, then transferring a membrane, sealing, respectively adding rabbit anti-human JAK3 (1: 500), incubating overnight at 4 ℃, adding horseradish peroxidase labeled goat anti-rabbit IgG (1: 5000) after rinsing, developing with ECL developer after rinsing, scanning and imaging by a Bio-Rad gel imaging system, and processing and analyzing by computer software. The control was referenced to glyceraldehyde phosphate dehydrogenase (GAPDH).
Grey scale analysis was performed on each band using Image J software to calculate the degradation rate of the compound to degrade JAK3 protein. The calculation formula is as follows:
the degradation rate of the compound on JAK3 protein in Jurkat cells is shown in the following table:
example 5CCK8 assay for inhibition of Jurkat cell proliferation (human leukemia T lymphocytes)
The inhibitory effect of the compounds on the proliferation of Jurkat cells was tested in vitro using the CCK8 assay. The method comprises the following specific steps:
culturing Jurkat cells in 1640 culture medium containing 10% calf serum, inoculating to 96-well plate, and culturing at 2 × 105Cells/well, 5% CO at 37 ℃2In an incubator. The compound was dissolved in Dimethylsulfoxide (DMSO) to give a solution having a concentration of 10mM, and then diluted with phosphate buffer to the desired concentration, and the diluted solution was added to the above 96-well plate at 2 wells per concentration and 10. mu.l per well, and each concentration was subjected to two parallel tests. DMSO was diluted accordingly in a gradient and added to the plate as a control.
Subjecting the 96-well plate to 5% CO at 37 deg.C2After culturing for 48 hours in the cell culture box, 10 μ l of CCK8 solution is added to each well, and the incubation is continued for 1-4 hours in the culture box. The 465nm light absorption value was measured.
The relative viability of the cells after compound treatment was calculated from the light absorption values. The calculation formula is as follows:
IC of compound on Jurkat cells was calculated by software50。
The in vitro proliferation inhibitory effect of the synthesized compounds on Jurkat cells is shown in table 1:
TABLE 1
The results show that the synthesized compound has good activity of inhibiting Jurkat cells.
EXAMPLE 6 in vivo anti-rheumatoid arthritis Activity of Compound (15)
The anti-rheumatoid arthritis effect of the compound (15) was determined in vivo using a Wistar rat rheumatoid arthritis induced by Freund's adjuvant as a model. The method comprises the following specific steps:
1) test sample
Sample preparation: compound (15).
2) Preparation method
Sample preparation: compound (15) dissolved in a physiological saline injection solution at the time of preparation
3) Animals and adjuvants
Wistar rats 18, male, weighing 170-200 g.
Adjuvant: complete Freund's Adjuvant (CFA), Sigma.
4) Test method
Wistar rats were randomly divided into 3 groups of 6 rats each. Blank control group, model group, compound (15) group (20mg/kg ip administration) were each included. The rats' left hind paw plantar skin was injected with 0.1mL of CFA to induce rheumatoid arthritis. The rats started dosing treatment on day 11 after model building, once a day, and the treatment is finished on day 22. After the treatment is finished, the volume of the left hind paw is measured, and the paw edema inhibition rate is calculated.
5) Test results
The inhibition rate of compound (15) on the foot swelling of rats induced by Freund's complete adjuvant is shown in Table 2:
TABLE 2
| Group of | Foot swelling inhibition ratio (%) |
| Blank control group | - |
| Model set | - |
| Compound (15) | 87 |
The results of the in vivo experiments show that the compound (15) has good anti-rheumatoid arthritis activity in vivo.
All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.
Claims (7)
1. A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier:
wherein:
a is absent or selected from C (═ O) X1; wherein X1 is absent or is (CR)12R13)eO, wherein R12、R13Each independently is H, e is an integer between 0 and 3;
w is absent or selected from O, NH, or X2C (═ O) X3; wherein X2 is absent, X3 is NH;
y is (CR)22R23)h(ii) a Wherein h is an integer between 0 and 9; wherein R is22、R23Each independently is H;
z is (CR)24R25)i(ii) a Wherein i is an integer between 0 and 9; wherein R is24、R25Each independently is H;
b is O;
x is C (═ O);
R1is H, R6Is C1-4Alkyl radical, R10Is H, R2Is H, R5Is C1-4Alkyl radical, R3Is H, R7Is H, R8Is H, R9Is H, R4Is H;
a is 5; b is 3; c is an integer between 0 and 9; d is 1.
2. The pharmaceutical composition of claim 1, wherein:
in said formula I, A is absent; w is X2C (═ O) X3, where X3 is NH and X2 is absent; y is (CR)22R23)hWherein R is22、R23Each independently is H, H is an integer between 1 and 6; z is (CR)24R25)iWherein R is24、R25Each independently is H, i is an integer between 1 and 6; c is 0; or
In said formula I, A is absent; w is absent or is O; y is (CR)22R23)hWherein R is22、R23Each independently is H, and H is an integer from 0 to 3; b is O; z is (CR)24R25)iWherein R is24、R25Each independently is H, i is an integer between 0 and 3; c is an integer between 1 and 6; or
Wherein a is C (═ O) X1, where X1 is (CR)12R13)eO, wherein e is an integer between 0 and 2, R12、R13Each independently is hydrogen; w is NH; y is (CR)22R23)hWherein R is22、R23Each independently is H, and H is an integer from 0 to 3; z is (CR)24R25)iWherein R is24、R25Each independently is H, i is an integer between 0 and 3; b is O; c is an integer between 1 and 4; or
In said formula I, A is absent; w is NH; y is (CR)22R23)hWherein R is22、R23Each independently is H, and H is an integer from 0 to 3; z is (CR)24R25)iWherein R is24、R25Each independently is H, i is an integer between 0 and 4; b is O; c is an integer between 1 and 6; or
In said formula I, A is absent; deletion of W; y is (CR)22R23)hWherein R is22、R23Each independently is H, and H is an integer from 0 to 3; z is (CR)24R25)iWherein R is24、R25Each independently is H, i is an integer between 0 and 3; b is O; c is an integer between 1 and 10.
3. The pharmaceutical composition of claim 1, wherein in formula I, c is an integer between 1 and 9.
4. Such asThe pharmaceutical composition of claim 1, wherein in formula I, R is6Is methyl.
5. The pharmaceutical composition of claim 1, wherein in formula I, R is5Is methyl.
6. The pharmaceutical composition of claim 1, wherein the compound is selected from the group consisting of:
7. a method of degrading JAK3 in vitro, the method comprising: administering to a subject in need thereof an inhibitory effective amount of a pharmaceutical composition according to any one of claims 1-6.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710783074.0A CN109422751B (en) | 2017-09-03 | 2017-09-03 | Compound with activity of degrading tyrosine protein kinase JAK3 |
| PCT/CN2018/103708 WO2019042443A1 (en) | 2017-09-03 | 2018-09-02 | Compound having tyrosine protein kinase jak3-degradation activity |
| CN201880004075.3A CN109963853B (en) | 2017-09-03 | 2018-09-02 | Compound with activity of degrading tyrosine protein kinase JAK3 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710783074.0A CN109422751B (en) | 2017-09-03 | 2017-09-03 | Compound with activity of degrading tyrosine protein kinase JAK3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109422751A CN109422751A (en) | 2019-03-05 |
| CN109422751B true CN109422751B (en) | 2022-04-22 |
Family
ID=65512838
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710783074.0A Active CN109422751B (en) | 2017-09-03 | 2017-09-03 | Compound with activity of degrading tyrosine protein kinase JAK3 |
| CN201880004075.3A Active CN109963853B (en) | 2017-09-03 | 2018-09-02 | Compound with activity of degrading tyrosine protein kinase JAK3 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880004075.3A Active CN109963853B (en) | 2017-09-03 | 2018-09-02 | Compound with activity of degrading tyrosine protein kinase JAK3 |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN109422751B (en) |
| WO (1) | WO2019042443A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109422751B (en) * | 2017-09-03 | 2022-04-22 | 上海美志医药科技有限公司 | Compound with activity of degrading tyrosine protein kinase JAK3 |
| CN114478532A (en) * | 2020-10-26 | 2022-05-13 | 上海美志医药科技有限公司 | Targeted Btk degradation compound and anti-tumor application thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1767533A1 (en) * | 2000-12-27 | 2007-03-28 | Celgene Corporation | N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor |
| CN102372717A (en) * | 2010-08-20 | 2012-03-14 | 和记黄埔医药（上海）有限公司 | Pyrrolopyrimidine compound and use thereof |
| CN103119045A (en) * | 2010-08-20 | 2013-05-22 | 和记黄埔医药（上海）有限公司 | Pyrrolopyrimidine compounds and uses thereof |
| CN103502249A (en) * | 2011-05-17 | 2014-01-08 | 普林斯匹亚生物制药公司 | Azaindole derivatives as tyrosine kinase inhibitors |
| CN103748096A (en) * | 2012-08-06 | 2014-04-23 | 美国艾森生物科学公司 | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases |
| CN104736569A (en) * | 2012-01-12 | 2015-06-24 | 耶鲁大学 | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| CN104853754A (en) * | 2012-11-20 | 2015-08-19 | 普林斯匹亚生物制药公司 | Azaindole derivatives as jak3 inhibitors |
| CN104910161A (en) * | 2009-07-02 | 2015-09-16 | 健泰科生物技术公司 | Pyrazolopyrimidine JAK inhibitor compounds and methods |
| CN105712998A (en) * | 2014-12-05 | 2016-06-29 | 上海润诺生物科技有限公司 | Azaindole derivatives, preparation method and applications thereof in medicine |
| CN106458993A (en) * | 2014-04-14 | 2017-02-22 | 阿尔维纳斯股份有限公司 | Imide-based modulators of proteolysis and associated methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3440082A1 (en) * | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| US10633386B2 (en) * | 2016-04-12 | 2020-04-28 | The Regents Of The University Of Michigan | BET protein degraders |
| WO2018119441A1 (en) * | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
| CN109422751B (en) * | 2017-09-03 | 2022-04-22 | 上海美志医药科技有限公司 | Compound with activity of degrading tyrosine protein kinase JAK3 |
-
2017
- 2017-09-03 CN CN201710783074.0A patent/CN109422751B/en active Active
-
2018
- 2018-09-02 WO PCT/CN2018/103708 patent/WO2019042443A1/en active Application Filing
- 2018-09-02 CN CN201880004075.3A patent/CN109963853B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1767533A1 (en) * | 2000-12-27 | 2007-03-28 | Celgene Corporation | N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor |
| CN104910161A (en) * | 2009-07-02 | 2015-09-16 | 健泰科生物技术公司 | Pyrazolopyrimidine JAK inhibitor compounds and methods |
| CN102372717A (en) * | 2010-08-20 | 2012-03-14 | 和记黄埔医药（上海）有限公司 | Pyrrolopyrimidine compound and use thereof |
| CN103119045A (en) * | 2010-08-20 | 2013-05-22 | 和记黄埔医药（上海）有限公司 | Pyrrolopyrimidine compounds and uses thereof |
| CN103502249A (en) * | 2011-05-17 | 2014-01-08 | 普林斯匹亚生物制药公司 | Azaindole derivatives as tyrosine kinase inhibitors |
| CN104736569A (en) * | 2012-01-12 | 2015-06-24 | 耶鲁大学 | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| CN103748096A (en) * | 2012-08-06 | 2014-04-23 | 美国艾森生物科学公司 | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases |
| CN104853754A (en) * | 2012-11-20 | 2015-08-19 | 普林斯匹亚生物制药公司 | Azaindole derivatives as jak3 inhibitors |
| CN106458993A (en) * | 2014-04-14 | 2017-02-22 | 阿尔维纳斯股份有限公司 | Imide-based modulators of proteolysis and associated methods of use |
| CN105712998A (en) * | 2014-12-05 | 2016-06-29 | 上海润诺生物科技有限公司 | Azaindole derivatives, preparation method and applications thereof in medicine |
Non-Patent Citations (2)
| Title |
|---|
| Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression;Bing Zhou等;《J. Med. Chem.》;20170324;第61卷;第462-481页 * |
| Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer;Longchuan Bai等;《Cancer Res.》;20170501;第77卷(第9期);第2476-2487页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109422751A (en) | 2019-03-05 |
| CN109963853B (en) | 2022-04-22 |
| CN109963853A (en) | 2019-07-02 |
| WO2019042443A1 (en) | 2019-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109422752B (en) | Compound with functions of inhibiting and degrading Bruton tyrosine protein kinase Btk activity | |
| CN109963844B (en) | Compound for inhibiting and degrading tyrosine protein kinase ALK | |
| US11459327B1 (en) | Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof | |
| CN109952304B (en) | CDK (CDK kinase) inhibiting and degrading compound | |
| KR20150082633A (en) | Novel Orally Bioavailable Breathing Control Modulating Compounds, and Methods of Using Same | |
| CN111662294A (en) | Compound with activity of degrading Btk | |
| EP4032890A1 (en) | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof | |
| CN109963853B (en) | Compound with activity of degrading tyrosine protein kinase JAK3 | |
| CN112979656A (en) | Compound for targeted degradation of BTK protein | |
| CN109937203B (en) | Compounds capable of inhibiting and degrading tyrosine protein kinase JAK1 or JAK2 activity | |
| CN113490669B (en) | Compound with activity of degrading Btk | |
| CN112243437A (en) | Acryloyl group-containing nuclear transport modulators and uses thereof | |
| CN117120421A (en) | 1,3, 4-oxadiazole thiocarbonyl compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | |
| US11884627B2 (en) | Compounds and compositions for treating conditions associated with LPA receptor activity | |
| CN116283764A (en) | Nitroquinoline prodrug, preparation method and application thereof | |
| WO2023201044A2 (en) | Jak inhibitor analogs, formulations, and uses thereof | |
| CN116120327A (en) | Beta-elemene 13, 14-position symmetrical disubstituted derivative and preparation method and application thereof | |
| JP2022531453A (en) | Thiazoline Anti-hyperalgesic manufacturing method and polymorphs | |
| WO2020027723A1 (en) | Bicyclic compounds as kinase modulators, methods and uses thereof | |
| CN116283763A (en) | Nitroquinoline prodrug, preparation method and application thereof | |
| CN114761011A (en) | Substituted (7H-pyrrolo [2,3-D ] pyrimidin-4-yl) amino compounds useful as JAK1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |